Skip to main content

Table 2 Genotypes of UGT1A and DPYD in mCRC patients

From: Examination of multiple UGT1A and DPYD polymorphisms has limited ability to predict the toxicity and efficacy of metastatic colorectal cancer treated with irinotecan-based chemotherapy: a retrospective analysis

Genotypes

No. of patients

%

UGT1A1*6

 G/G

431

65.2%

 G/A

198

30.0%

 A/A

32

4.8%

UGT1A1*27

 C/C

535

98.2%

 C/A

10

1.8%

UGT1A1*28

 TA6/TA6

501

75.8%

 TA6/TA7

152

23.0%

 TA7/TA7

8

1.2%

UGT1A7

  UGT1A7*1/*1

196

36.0%

  UGT1A7*1/*2

103

18.9%

  UGT1A7*1/*3

131

24.0%

  UGT1A7*2/*2

31

5.7%

  UGT1A7*2/*3

53

9.7%

  UGT1A7*3/*3

31

5.7%

UGT1A9*22

 T9/T9

99

18.2%

 T9/T10

442

81.1%

 T10/T10

4

0.7%

DPYD*5

 A/A

256

51.6%

 A/G

199

40.1%

 G/G

41

8.3%

DPYD*2A

 G/G

495

99.8%

 G/A

1

0.2%

DPYD c.1896 T > C

 T/T

395

79.6%

 T/C

96

19.4%

 C/C

5

1.0%

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us